Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › chronic inflammatory demyelinating polyneuropathy

Chronic inflammatory demyelinating polyneuropathy

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for chronic inflammatory demyelinating polyneuropathy

6 trials tracked for chronic inflammatory demyelinating polyneuropathy: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 281 citations.

6Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 3 Other / NA 1
  1. Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed · 281 cited
  2. Phase 3 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed
  3. Phase 2 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Completed
  4. Phase 2 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Completed
  5. Phase 2 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed
  6. N/A Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Chronic inflammatory demyelinating polyneuropathy: what the trials found

Clinical trials for inflammatory neuropathies demonstrate significant improvements in mobility and strength using specific immunoglobulin treatments. One study showed that IgPro20 (low dose) resulted in a statistically significant reduction in the percentage of subjects experiencing CIDP relapse or withdrawal during subcutaneous treatment (p=0.007). Additionally, this intervention showed no significant change in INCAT scores (p=0.005) and a measurable decrease in mean grip strength decline compared to other groups (p=0.004).

Another study utilizing a 10% liquid formulation of human immunoglobulin demonstrated consistent improvements in Adjusted INCAT Scores across multiple measurement points.

Recent results — preliminary, needs further review

  • Immune Globulin Subcutaneous (Human) showed a mean change of 0.03 in Emotional Well-being, 0.08 in Pain, and an increase of 5.6 in Limb Motor Strength Testing over 24 weeks (not yet corroborated).

For the clinician treating this condition

  • IgPro20 (low dose) is associated with a significant reduction in CIDP relapse rates during subcutaneous administration.
  • Human immunoglobulin formulations have demonstrated consistent improvements in INCAT scores for patients with inflammatory neuropathies.

AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Efgartigimod alfa targets FcRn across three neuroimmune conditions
Diabetes & Endocrinology Sys. Review
Efgartigimod alfa targets FcRn across three neuroimmune conditions New drug shows promise for rare autoimmune nerve conditions
Efgartigimod alfa blocks FcRn to lower circulating IgG. It is approved for myasthenia gravis and CIDP, but not Guillain-Barré syndrome.
A new medication targets the immune system to treat rare nerve conditions, though it is not yet approved for all patients.
Frontiers Sep 16, 2026
Case report highlights diagnostic challenges between POEMS syndrome and CIDP
Oncology Sys. Review
Case report highlights diagnostic challenges between POEMS syndrome and CIDP Misdiagnosis of rare nerve disorder highlights need for vigilance
This case report and literature review describes a single patient with POEMS syndrome who was initially misdiagnosed with CIDP.
A single patient's journey from a wrong diagnosis to the truth reveals how easily rare nerve conditions can be missed.
Frontiers Apr 30, 2026